HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chanelle McCoy Health Claims Leadership In UK CBD Market Following FSA List Inclusion

Executive Summary

Irish synthetic cannabidiol supplier and Pureis brand owner Chanelle McCoy Health says early inclusion on the UK food regulator's list of validated CBD products sets the company apart from the competition. Meanwhile, an additional CBD supplier - Rokshaw - has also been added. 

You may also be interested in...



UK CBD Limbo Continues – Full List Of ‘Legal’ Products Delayed Until June

A provisional list of CBD products that can continue to legally be sold in the UK has been issued by the Food Standards Agency. However the list currently only includes products from three suppliers and will not be complete until June 2021, meaning the vast majority of companies face a nervy wait.

The Future Of Europe's CBD Market Lies With Big Pharma And OTC Pathway

The "shakers and movers" in the European cannabidiol market in the next two to three years will be big pharma, says Irish synthetic CBD specialist Chanelle McCoy Health. With its purported health benefits, CBD will also need to go the way of OTC drugs, with medicinal claims supported by clinical trials, the firm predicts. 

EU Bans Titanium Dioxide In Supplements, Drugs Given Reprieve, For Now

Titanium dioxide is now officially banned as an ingredient in foods and dietary supplements in the European Union on safety grounds. However, manufacturers can still place products containing the chemical compound on the market for six months, and then any products still on the market can remain until their expiry date. Meanwhile, the European Commission and pharmaceutical companies have three years to find titanium dioxide alternatives for medicines, or justify why it should continue to be used.

Topics

UsernamePublicRestriction

Register

RS151280

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel